BR0210261A - Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes - Google Patents

Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes

Info

Publication number
BR0210261A
BR0210261A BR0210261-7A BR0210261A BR0210261A BR 0210261 A BR0210261 A BR 0210261A BR 0210261 A BR0210261 A BR 0210261A BR 0210261 A BR0210261 A BR 0210261A
Authority
BR
Brazil
Prior art keywords
derivatives
apomorphine
prodrugs
pharmaceutical formulations
efficient administration
Prior art date
Application number
BR0210261-7A
Other languages
English (en)
Inventor
Hakan Wikstrom
Durk Djkstra
Thomas Ivo Franchiscus Cremers
Original Assignee
Axon Biochemicals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Biochemicals Bv filed Critical Axon Biochemicals Bv
Publication of BR0210261A publication Critical patent/BR0210261A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS PARA A ADMINISTRAçãO EFICIENTE DE APOMORFINA, 6aR-(-)-N-PROPIL-NORAPOMORFINA E SEUS DERIVADOS E PRó-DROGAS DESTES". A presente invenção refere-se a uma formulação farmacêutica para o tratamento de uma doença selecionada do grupo consistindo em doença de Parkinson, síndrome das pernas inquietas, disfunção erétil masculina e disfunção sexual feminina. A composição compreende, pelo menos um membro selecionado dentre o grupo consistindo em apomorfina, 6aR-(-)-N-propil-norapomorfina e seus derivados e suas pró-drogas na forma de base, ou de sal farmaceuticamente aceitável ou solvatos destes, como um ingrediente ativo em uma preparação farmacêutica adequada para administração oral/intraduodenal.
BR0210261-7A 2001-06-08 2002-06-07 Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes BR0210261A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102036A SE0102036D0 (sv) 2001-06-08 2001-06-08 Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PCT/SE2002/001106 WO2002100377A1 (en) 2001-06-08 2002-06-07 PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF

Publications (1)

Publication Number Publication Date
BR0210261A true BR0210261A (pt) 2004-07-20

Family

ID=20284413

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210261-7A BR0210261A (pt) 2001-06-08 2002-06-07 Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes

Country Status (19)

Country Link
US (2) US20040220205A1 (pt)
EP (1) EP1401398A1 (pt)
JP (1) JP2005508865A (pt)
KR (2) KR20090085162A (pt)
CN (1) CN1286451C (pt)
AU (1) AU2002309429B2 (pt)
BR (1) BR0210261A (pt)
CA (1) CA2449571A1 (pt)
CZ (1) CZ20033332A3 (pt)
EA (1) EA008409B1 (pt)
HU (1) HUP0400200A3 (pt)
IL (1) IL158898A0 (pt)
MX (1) MXPA03011314A (pt)
NO (1) NO20035438L (pt)
NZ (1) NZ529623A (pt)
PL (1) PL367883A1 (pt)
SE (1) SE0102036D0 (pt)
WO (1) WO2002100377A1 (pt)
ZA (1) ZA200309048B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
US20070065463A1 (en) 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TWI404702B (zh) 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
JP2011526889A (ja) * 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
US20120196889A1 (en) 2009-02-25 2012-08-02 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
KR101374500B1 (ko) * 2012-10-09 2014-03-13 울산대학교 산학협력단 Ｒ(-)-프로필노르아포모르핀을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
MX2017008382A (es) * 2014-12-23 2018-04-30 Neuroderm Ltd Formas cristalinas de apomorfina y sus usos.
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
EP4578461A3 (en) 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
US20180280465A1 (en) 2015-09-28 2018-10-04 Ever Neuro Pharma Gmbh Aqueous composition of apomorphine for subcutaneous administration
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972600B1 (en) 2019-05-21 2026-02-18 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US20240025857A1 (en) 2020-11-17 2024-01-25 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP2025520542A (ja) 2022-06-15 2025-07-03 エバー ニューロ ファーマ ゲーエムベーハー アポモルヒネプロドラッグおよびその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
DE2717001C2 (de) * 1977-04-18 1984-06-20 Karl O. Helm Ag, 2000 Hamburg Arzneimittel mit antithrombotischer Wirkung
US4120860A (en) * 1977-05-10 1978-10-17 Cooper Lab 3-Aryl-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5222236A (en) * 1988-04-29 1993-06-22 Overdrive Systems, Inc. Multiple integrated document assembly data processing system
CA2013485C (en) * 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US6506765B2 (en) * 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
EP1846410B1 (en) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators

Also Published As

Publication number Publication date
CA2449571A1 (en) 2002-12-19
EA200400007A1 (ru) 2004-04-29
CZ20033332A3 (cs) 2004-12-15
WO2002100377A1 (en) 2002-12-19
SE0102036D0 (sv) 2001-06-08
CN1286451C (zh) 2006-11-29
NO20035438D0 (no) 2003-12-05
MXPA03011314A (es) 2004-12-06
KR20040007644A (ko) 2004-01-24
US20080145417A1 (en) 2008-06-19
HUP0400200A3 (en) 2008-03-28
KR20090085162A (ko) 2009-08-06
ZA200309048B (en) 2004-11-22
CN1531420A (zh) 2004-09-22
AU2002309429B2 (en) 2007-08-09
PL367883A1 (en) 2005-03-07
JP2005508865A (ja) 2005-04-07
HUP0400200A2 (hu) 2004-06-28
EP1401398A1 (en) 2004-03-31
EA008409B1 (ru) 2007-04-27
NO20035438L (no) 2004-02-05
IL158898A0 (en) 2004-05-12
US20040220205A1 (en) 2004-11-04
NZ529623A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
EA200400007A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
UY26139A1 (es) Composiciones de medicamentos a base de compuestos anticolinérgicamente activos y beta- miméticos
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
MXPA03005464A (es) Agentes antivirales.
GEP20053510B (en) Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
AR053680A1 (es) Composicion
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
PY0228832A (es) Formulaciones farmaceuticas de 5,7,14-triazatetra-ciclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
ITMI20022674A1 (it) Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
PT1173181E (pt) Composicao compreendendo os inibidores da fosfodiesterase para tratar disfuncoes sexuais
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
AR046226A1 (es) Formulaciones farmaceuticas que contienen saborizante con caracteristicas farmaceuticas mejoradas
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
IL148739A0 (en) 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
CA2429793A1 (en) Interferon therapeutic effect enhancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.